Objective:The aim of this study was to compare the serum CA125 regression in advanced ovarian carcinoma patients treated with paclitaxel/platinum (TP) and platinum/epirubicin/ifosfamide (PAC) during early chemotherapy.The relationship between survival and CA125 regression during first line chemotherapy was evaluated.Methods:This retrospective investigation assessed 122 and 95 patients with stages IIc-IV ovarian carcinoma who underwent initial surgery followed by TP or PAC chemotherapy,respectively.Only epithelial ovarian cancers were included.CA125 half-life was calculated by mono-compartmental logarithmic regression.Every patient’s nadir CA125 concentration was also studied.T-test was used in comparing CA125 half-life and nadir CA125 between two groups.Survival analyses for progression-free survival (PFS) and overall survival (OS) used univariate (Kaplan-Meier) and multivariate (Cox) models for all of the patients.Results:There was not significant difference in CA125 half-life and nadir CA125 concentration between two groups (P > 0.05).CA125 half-life and nadir CA125 concentration had a univariate prognostic value for PFS and OS (P < 0.0001) in all of the patients.However pre-chemotherapy CA125 and different chemotherapy agents were not prognostic factors for PFS and for OS (P > 0.05,for each).In Cox models,CA125 half-life (P=0.0006),residual tumour (P < 0.0001),and nadir concentration (P=0.0032) were significant prognostic factors for disease free survival (DFS).For OS,CA125 half-life (P=0.0013),residual tumor (P < 0.0001),and nadir concentration (P=0.0118) were also the significant prognostic factors.Conclusion:There isn’t significant difference in serum CA125 regression between patients who are treated with PAC or PT during early chemotherapy.CA125 half-life and nadir CA125 concentration are independent prognostic factor in advanced ovarian cancer. Objective: The aim of this study was to compare the serum CA125 regression in advanced ovarian carcinoma patients treated with paclitaxel / platinum (TP) and platinum / epirubicin / ifosfamide (PAC) during early chemotherapy. The relationship between survival and CA125 regression during first line chemotherapy was evaluated. Methods: This retrospective investigation assessed 122 and 95 patients with stages IIc-IV ovarian carcinoma who underwent initial surgery followed by TP or PAC chemotherapy, respectively. Patients with epithelial ovarian cancers were included. CA125 half-life was calculated by mono- The compartmental logarithmic regression. Every patient’s nadir CA125 concentration was also studied.T-test was used in comparing CA125 half-life and nadir CA125 between two groups. Survival analyzes for progression-free survival (PFS) and overall survival (OS) used univariate Kaplan-Meier) and multivariate (Cox) models for all of the patients. Results: There was no significant difference in CA125 half-life and nad CA125 concentration between a univariate prognostic value for PFS and OS (P <0.0001) in all of the patients. Host pre-chemotherapy CA125 and different chemotherapy agents were not prognostic factors for PFS and for OS. In Cox models, CA125 half-life (P = 0.0006), residual tumor (P <0.0001), and nadir concentration (P = 0.0032) Factors for disease free survival (DFS) .For OS, CA125 half-life (P = 0.0013), residual tumor (P 0.0001), and nadir concentration (P = 0.0118) were also the significant prognostic factors.Conclusion: There isn ’ t significant difference in serum CA125 regression between patients who were treated with PAC or PT during early chemotherapy. CA125 half-life and nadir CA125 concentration are independent prognostic factor in advanced ovarian cancer.